Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase I/IIa Dose Escalation Safety and Efficacy Study of Human Embryonic Stem Cell-Derived Retinal Pigment Epithelium Cells Transplanted Subretinally in Patients With Advanced Dry-Form Age-Related Macular Degeneration (Geographic Atrophy)

NCT02286089 is registered in ClinicalTrials.gov with Hoffmann-La Roche as lead sponsor.

NCT NCT02286089
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02286089 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase I/IIa Dose Escalation Safety and Efficacy Study of Human Embryonic Stem Cell-Derived Retinal Pigment Epithelium Cells Transplanted Subretinally in Patients With Advanced Dry-Form Age-Related Macular Degeneration (Geographic Atrophy)
Lead sponsor
Hoffmann-La Roche
Phase
Phase 1/2
Overall status
Active, not recruiting
Start date
April 1, 2015
Completion date
January 31, 2031
Enrollment
24 (actual)
Sites
7

Conditions

As the registry lists them; a condition with its own page is linked.

age-related macular degeneration